Toyochem Develops Soft Skin Polyurethane-based Pressure-Sensitive Adhesives

February 24, 2021

Toyochem Co. has released a new line of “Soft Skin” polyurethane-based pressure-sensitive adhesives (PSAs) designed to meet the growing demand for safe, low-trauma medical devices formulated for sensitive skin individuals. Suitable applications include surgical tapes and dressing films customized for the medical and healthcare fields.

The new adhesive system offers high moisture permeability and low skin exfoliation for pain-free removal or repositioning of the adhesive material. In addition, the new compositions do not contain silicones or other substances that may contaminate coatings lines or processing environments.
Drawing on its expertise in urethane chemistry in the development of protective films for the electronics industry, Toyochem engineered a medical-grade urethane composition with a uniquely soft and flexible urethane-based composition. The product adheres well to the skin while causing very low trauma to the keratin layer when the dressing is removed or repositioned. “The challenge is finding the right balance between adhesion and release,” said Nao Nakamura, general manager of Toyochem’s adhesives division.
Nakamura added, “Materials for medical devices and dressing must have the elasticity to conform to skin surfaces and movement in order to prevent water, dirt, or bacteria from entering and infecting the wound. They also need to have the right amount of release to prevent trauma to the tender skin surrounding it. With the new development, we’re able to strike a fine balance that meets both requirements.”
Moreover, Toyochem’s new urethane PSA system demonstrates exceptional moisture permeability with water vapor transmission rates of 2,000g/m2/24 hours, achieving values that are considerably higher than those of conventional acrylic PSAs. Poor moisture permeability can trap heat and water vapors between the skin and adhesive layer, often leading to skin irritation, maceration, and even bacterial growth. Toyochem’s PSA product, however, is designed to substantially raise the water vapor transmission ability of the adhesive layer, allowing moisture to be evaporated to the outside of the adhesive material.
At present, silicones are widely used in the manufacturing of wound management devices, due to their biocompatibility. The new PSAs from Toyochem, however, is silicone-free and have been proven safe for human skin contact. They can be customized to meet International Standards ISO 10993-1, making it a more user- and cost-friendly alternative to silicone adhesives.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version